Thrombotic thrombocytopenia purpura (TTP) in the background of systemic lupus erythematous (SLE) remains rare with an incidence of about 2%.
Introduction
Thrombotic thrombocytopenia purpura (TTP), is a rare life threatening disease presenting with microangiopathic haemolytic anaemia, thrombocytopenia, renal abnormalities, neurological abnormalities and a fever. However, the urgency for treatment of patients with plasma exchange has resulted in a change in the diagnostic criteria.
It has been revised from the earlier classic pentad, found in only 5% of cases, to the current dyad of thrombocytopenia and microangiopathic hemolytic anaemia, with no clinically apparent alternative explanation for thrombocytopenia and anaemia [1] . TTP occurring in the background of systemic lupus erythematous (SLE), remains rare. The incidence of TTP in SLE is thought to be approximately 2% [2] . The pathophysiologic feature of TTP has been described as severe deficiency of von Willebrand Factor (vWF) cleaving metalloproteinase (ADAMTS-13), which normally cleaves the unusually large vWF into smaller and less adhesive vWF moiety. This deficiency is thought to be possibly secondary to the presence of an IgG antibody inhibiting ADAMTS-13 activity, inhibition that finally allows the presence of units of unusually large vWF which is responsible for the microvascular thrombosis, hemolysis, and thrombocytopenia [3] . TTP is difficult to differentiate from a flare of SLE because of overlapping features. Both can present with haemolytic anaemia, thrombocytopenia, fevers, renal and neurological dysfunction, often complicating the diagnosis. The haemolytic anaemia in TTP is microangiopathic while in a flare of SLE autoimmune haemolytic anaemia is the commonest cause. In the background of SLE, a number of disease entities can cause microangiopathic haemolytic anaemia and thrombocytopenia including antiphospholipid syndrome, disseminated intravascular coagulation, malignant hypertension, systemic vasculitis as well as a HELLP syndrome in any female of child bearing age [4] . The mainstay of treatment of TTP even in the background of SLE remains plasma exchange [5] .
Corticosteroids are used initially to achieve relatively rapid immunosuppression. There is some prospective evidence that higher doses of methylprednisolone (10 mg/kg/day) are more effective than lower doses (1 mg/kg/day) [6] . Rituximab is effective in patients who have failed to respond to plasma exchange and steroids [7] .
Patient and observation
A 40-year-old female of Asian origin, known to have SLE diagnosed three years ago, presented to our institution with a three-day history of jaundice, gross hematuria and bleeding from her gums. Apart from generalized weakness and intermittent headaches, the patient denied Plasma exchange was immediately initiated at a dose of 1 volume on alternate days and the steroids at 1mg/kg were continued. Alternate day plasma exchange as opposed to the recommended daily plasma exchange was pursued due to the difficulty in obtaining an adequate number of fresh frozen plasma units. After three sessions of plasma exchange, the patient's platelet count increased to 152x109 /L, her LDH level normalized and her headaches markedly improved. The platelet count continued to progressively rise. On discharge, four weeks later, the patient's hemoglobin count was 10.8g/dl, platelet count of 228x109/ L and she had a normal total bilirubin. Her steroids were gradually tapered and she was scheduled to follow in our outpatient clinic. Figure 1 represents the platelet count from admission to discharge of the patient.
Discussion
The initial diagnosis in our patient was thought to be a flare of SLE leading to the autoimmune mediated destruction of red blood cells and platelets. However, the peripheral blood smear was remarkable for schistocytes and not spherocytes. In addition, our patient had a Even though not sensitive or specific, a severe deficiency of ADAMTS-13 activity and the presence of ADAMTS-13 inhibitors in the appropriate clinical setting can confirm the presence of TTP [8] .
Normal ADAMTS-13 activity should clue one into looking at other causes of MAHA and low platelets [9] . Interestingly, in patient with SLE, especially with a positive anti-dsDNA, and concomitant TTP, less than 10% showed ADAMTS-13 activity [8] . In addition, the decreased level of ADAMTS-13 activity correlated with increased SLE related tissue damage [10] . The diagnosis of TTP is a medical emergency with plasma exchange being the mainstay of treatment. Plasma exchange should be started immediately and has shown to decrease mortality for an estimated 90% to less than 10% [11] . Hence now the dyad of microangiopathic haemolytic anaemia and thrombocytopenia with no clinically apparent explanation should be treated as TTP [1] .
Unfortunately, in our patient's case the diagnosis of TTP was delayed by a week due to the delay in the report of the peripheral blood film.
Plasma exchange is usually given concomitantly with steroid [4] . Once the platelets have normalized for 48 hours, the plasma exchange can be halted and steroid gradually tapered [4, 12] . Cyclophosphamide and rituximab (anti-CD 20) have been reportedly used as a salvage treatment in refractory TTP [12, 13] . This case report demonstrates that not all hemolytic anaemia in SLE is immune mediated. Peripheral blood film is mandatory to evaluate anemias even though it is often over looked. Microangiopathic haemolytic anaemia in the background of SLE can have a number of etiologies including TTP. Diagnosing TTP in the background of SLE poses a challenge. Diagnosis and appropriate management was possible in this patient albeit a week after admission. The patient responded well and was discharged after complete recovery.
Conclusion
Hemolytic anemia and thrombocytopenia must always raise the suspicion on TTP especially in the appropriate clinical setting. SLE and
